Will EUAs and Revised CMS Regulations Outlast COVID?

article image

Assessing the long-term prospects for pandemic-focused product approvals and payment rules.

Economist and Nobel laureate Milton Friedman cautioned, “Nothing is so permanent as a temporary government program,” in his 1984 book, Tyranny of the Status Quo. While Friedman cited US agricultural subsidies as an example, a more compelling illustration is Bismarck’s imposition of a tax on champagne corks to fund the German fleet. The fleet ended up on the ocean floor, while the tax remains.

This principle comes to mind as the medtech industry and the healthcare system as a whole are having to operate under a variety of what are being called temporary policies designed to expedite treatment of COVID-19.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: